Osteoporosis is a state in which there is excessive loss of bone. This leads to the weakening of bones and the bone may even break from minor bumps. The individual loses the bone density in the hip and spine. Osteoporosis is treated with various oral and injectable medications. As per National Osteoporosis Foundation, calcium deficiency has caused a substantial increase in osteoporosis prevalence among postmenopausal women. This is one of the main drivers of anti-osteoporosis therapy and fracture healing demand.
The market for osteoporosis drugs is expected to reach rise at a CAGR of 5.2 percent during the forecast period. Extreme fractures, which can have a negative impact on a patient's wellbeing, are driving the growth of the Osteoporosis Drugs Market.
Anti-osteoporosis and fracture recovery are most often treated with oral medications. The growing demand for non-invasive therapeutics has aided the market's growth. Pharmaceutical manufacturers are expected to focus more on improving their production capability. Scientific growth prospects for product effectiveness and minimal complications have led to increased investment in innovation and new product releases. Their efforts have resulted in the growth of the anti-osteoporosis and fracture healing markets. Large-scale closures and shutdowns have halted manufacturing operations around the world, affecting the development of the anti-osteoporosis treatment and fracture healing markets. Leading biopharmaceutical companies are currently concentrating their efforts on finding a coronavirus cure, which has caused a pause in research and development.
Increased healthcare spending has resulted in the growth of healthcare infrastructure and a rise in healthcare facilities. It is anticipated that as the number of trauma centers grows, anti-osteoporosis treatment and fracture healing will become more available, propelling the market forward. Within the global anti-osteoporosis therapy and fracture healing industry, bisphosphonates, estrogen therapy, and selective estrogen receptor modulators are considered the main drug groups. However, most of these medicines were developed decades ago, and their patents have expired or will expire within the forecast period.
Throughout the forecast period, bisphosphonates will continue to hold a global share of over 49% of the drug class. This is attributed to a rise in patient demand for target-specific therapeutics and a change in prescribing trends toward bisphosphonates. Oral and injectable medications are available for anti-osteoporosis treatment and fracture healing. With the growing demand for non-invasive therapeutics, the oral drug is projected to hold more than 65 percent of revenue share in anti-osteoporosis therapy and fracture healing. Factors including the growing prevalence of needle phobia and needle stick wounds are pushing up demand for oral therapeutics. The high cost of injectable drugs furthermore limits its expansion into the anti-osteoporosis and fracture healing markets. Hospital pharmacies are forecast to generate 2 times more revenue by 2025 than they did in 2019. Throughout the forecast period, the rising cases of osteoporosis and trauma fractures are expected to fuel demand for anti-osteoporosis therapy and fracture healing. Online pharmacy, will also experience rapid growth in the coming decade as e-commerce operations become more widely adopted.
Get a brochure of this research study Click Here
Various regulatory agencies, including Europe’s EMA, the United States FDA, and others, have recently made headlines. New medications for the treatment of osteoporosis have been approved by the FDA, the Medicines and the MHRA, and others. Across the forecast period, approval and launch of new drugs are expected to drive global Anti-Osteoporosis and Fracture Healing Market development.
ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET SEGMENTATION:
By Drug Type
- Estrogen or Hormone Replacement Therapy
By Route Of Administration:
By Distribution Channel:
- Hospital Pharmacies
- Drug stores
- Retail Pharmacies
- North America
- Latin America
- Asia Pacific
- Middle East & Africa
North America is likely to be the most profitable region throughout forecast period. Increased compliance with regulatory standards is one of the main factors promoting expansion. The demand for anti-osteoporosis therapy and fracture healing is expected to grow as the drug's acceptance and commercialization become more common in the United States. In addition, the majority of the big players in the anti-osteoporosis and fracture healing markets are headquartered in the United States. The demand for diagnosis and care is expected to open up new market opportunities. Furthermore, the cost of medicines is comparatively higher in countries like the United States, resulting in high-profit margin businesses operating there.
In GCC countries, there is relatively less understanding of osteoporosis and the treatment options available, rendering anti-osteoporosis therapy and fracture healing market growth less lucrative. The population of GCC nations has a lower purchasing power parity, resulting in lower healthcare spending. Due to a lack of qualified medical practitioners and a weak healthcare system, diagnosis and treatment rates are lower. The demand for anti-osteoporosis therapy and fracture healing in GCC countries is expected to rise steadily, with a CAGR of around 3%.
China, one of the world's most populous nations, presents the market with significant growth potential. Over the last decade, the country has also expanded its manufacturing capability, becoming the leading supplier of drugs and raw materials in the anti-osteoporosis and fracture healing markets. Following India, Malaysia is the second largest market in South Asia for anti-osteoporosis treatment and fracture healing. The country is expected to rise at a rate of more than 3% this year. Malaysia is one of the most appealing medical tourism destinations, with lower healthcare rates than the United States or the United Kingdom.
FEW KEY PLAYERS IN ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET :
- Eli Lilly and Company
- Pfizer Inc.
- Amgen Inc.
- Merck and Company, Inc.
- Novartis International AG
- F. Hoffmann La Roche Ltd.
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline Plc.
- Other Key & Niche Players